194 related articles for article (PubMed ID: 27341022)
1. Characterisation of the oxysterol metabolising enzyme pathway in mismatch repair proficient and deficient colorectal cancer.
Swan R; Alnabulsi A; Cash B; Alnabulsi A; Murray GI
Oncotarget; 2016 Jul; 7(29):46509-46527. PubMed ID: 27341022
[TBL] [Abstract][Full Text] [Related]
2. The expression and prognostic significance of retinoic acid metabolising enzymes in colorectal cancer.
Brown GT; Cash BG; Blihoghe D; Johansson P; Alnabulsi A; Murray GI
PLoS One; 2014; 9(3):e90776. PubMed ID: 24608339
[TBL] [Abstract][Full Text] [Related]
3. The differential expression of omega-3 and omega-6 fatty acid metabolising enzymes in colorectal cancer and its prognostic significance.
Alnabulsi A; Swan R; Cash B; Alnabulsi A; Murray GI
Br J Cancer; 2017 Jun; 116(12):1612-1620. PubMed ID: 28557975
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral budding as a potential parameter of tumor progression in mismatch repair-proficient and mismatch repair-deficient colorectal cancer patients.
Lugli A; Vlajnic T; Giger O; Karamitopoulou E; Patsouris ES; Peros G; Terracciano LM; Zlobec I
Hum Pathol; 2011 Dec; 42(12):1833-40. PubMed ID: 21664647
[TBL] [Abstract][Full Text] [Related]
5. Urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer.
Minoo P; Baker K; Baumhoer D; Terracciano L; Lugli A; Zlobec I
Hum Pathol; 2010 Jan; 41(1):70-8. PubMed ID: 19740518
[TBL] [Abstract][Full Text] [Related]
6. Systematic assessment of protein phenotypes characterizing high-grade tumour budding in mismatch repair-proficient colorectal cancer.
Karamitopoulou E; Lugli A; Panayiotides I; Karakitsos P; Peros G; Rallis G; Patsouris ES; Terracciano L; Zlobec I
Histopathology; 2010 Aug; 57(2):233-43. PubMed ID: 20716165
[TBL] [Abstract][Full Text] [Related]
7. Expression of an oxysterol-metabolizing enzyme in colorectal cancer and its relation to tumor cell behavior and prognosis.
Kim KH; Park YL; Park SY; Joo YE
Pathol Res Pract; 2023 Nov; 251():154875. PubMed ID: 37820439
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the immunological microenvironment of tumour buds and its impact on prognosis in mismatch repair-proficient and -deficient colorectal cancers.
Zlobec I; Minoo P; Terracciano L; Baker K; Lugli A
Histopathology; 2011 Sep; 59(3):482-95. PubMed ID: 22034888
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrial oxysterol biosynthetic pathway gives evidence for CYP7B1 as controller of regulatory oxysterols.
Kakiyama G; Marques D; Takei H; Nittono H; Erickson S; Fuchs M; Rodriguez-Agudo D; Gil G; Hylemon PB; Zhou H; Bajaj JS; Pandak WM
J Steroid Biochem Mol Biol; 2019 May; 189():36-47. PubMed ID: 30710743
[TBL] [Abstract][Full Text] [Related]
10. Tumor Budding and PDC Grade Are Stage Independent Predictors of Clinical Outcome in Mismatch Repair Deficient Colorectal Cancer.
Ryan É; Khaw YL; Creavin B; Geraghty R; Ryan EJ; Gibbons D; Hanly A; Martin ST; O'Connell PR; Winter DC; Sheahan K
Am J Surg Pathol; 2018 Jan; 42(1):60-68. PubMed ID: 29112018
[TBL] [Abstract][Full Text] [Related]
11. Deficient mismatch repair phenotype is a prognostic factor for colorectal cancer in elderly patients.
Aparicio T; Schischmanoff O; Poupardin C; Soufir N; Angelakov C; Barrat C; Levy V; Choudat L; Cucherousset J; Boubaya M; Lagorce C; Guetz GD; Wind P; Benamouzig R
Dig Liver Dis; 2013 Mar; 45(3):245-50. PubMed ID: 23102497
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of cell cycle and apoptosis regulatory proteins in mismatch repair-proficient colorectal cancer: a tissue microarray-based approach.
Tornillo L; Lugli A; Zlobec I; Willi N; Glatz K; Lehmann F; Spichtin HP; Maurer R; Stoios D; Sauter G; Terracciano L
Am J Clin Pathol; 2007 Jan; 127(1):114-23. PubMed ID: 17145638
[TBL] [Abstract][Full Text] [Related]
13. Loss of APAF-1 expression is associated with tumour progression and adverse prognosis in colorectal cancer.
Zlobec I; Minoo P; Baker K; Haegert D; Khetani K; Tornillo L; Terracciano L; Jass JR; Lugli A
Eur J Cancer; 2007 Apr; 43(6):1101-7. PubMed ID: 17350821
[TBL] [Abstract][Full Text] [Related]
14. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
[TBL] [Abstract][Full Text] [Related]
15. An alternative pathway in colorectal carcinogenesis based on the mismatch repair system and p53 expression in Korean patients with sporadic colorectal cancer.
Kim HR; Kim HC; Yun HR; Kim SH; Park CK; Cho YB; Yun SH; Lee WY; Chun HK
Ann Surg Oncol; 2013 Nov; 20(12):4031-40. PubMed ID: 22732839
[TBL] [Abstract][Full Text] [Related]
16. Changes in brain oxysterols at different stages of Alzheimer's disease: Their involvement in neuroinflammation.
Testa G; Staurenghi E; Zerbinati C; Gargiulo S; Iuliano L; Giaccone G; Fantò F; Poli G; Leonarduzzi G; Gamba P
Redox Biol; 2016 Dec; 10():24-33. PubMed ID: 27687218
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of β-2-microglobulin expression in colorectal cancers stratified by mismatch repair status.
Koelzer VH; Baker K; Kassahn D; Baumhoer D; Zlobec I
J Clin Pathol; 2012 Nov; 65(11):996-1002. PubMed ID: 22859396
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of mammalian sterile20-like kinase 1 in colorectal cancer.
Minoo P; Zlobec I; Baker K; Tornillo L; Terracciano L; Jass JR; Lugli A
Mod Pathol; 2007 Mar; 20(3):331-8. PubMed ID: 17277767
[TBL] [Abstract][Full Text] [Related]
19. Expression of oxysterol pathway genes in oestrogen-positive breast carcinomas.
Kloudova A; Brynychova V; Vaclavikova R; Vrana D; Gatek J; Mrhalova M; Kodet R; Soucek P
Clin Endocrinol (Oxf); 2017 Jun; 86(6):852-861. PubMed ID: 28342201
[TBL] [Abstract][Full Text] [Related]
20. Epithelial-mesenchymal transition (EMT) protein expression in a cohort of stage II colorectal cancer patients with characterized tumor budding and mismatch repair protein status.
Kevans D; Wang LM; Sheahan K; Hyland J; O'Donoghue D; Mulcahy H; O'Sullivan J
Int J Surg Pathol; 2011 Dec; 19(6):751-60. PubMed ID: 21791486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
